Mimix™ Colorectal Cancer Panel, ctDNA Reference Standard

Improve your MRD assay validations using the new Colorectal Cancer Panel ctDNA Reference Standard. It is a well characterized, cell line-derived control material manufactured under ISO 9001:2015 and ISO 13485:2016 that contains 10 clinically relevant variants across 10 genes.

Clearance sale: Discounted pricing on selected cfDNA inventory. Limited availability.*

*This pricing promotion is only valid on selected products and while stocks last. Not valid in Italy and China. The promotion cannot be combined with any other promotions, discounts, or offers. Conditions of the promotions may change, and Revvity may void, change, cancel, suspend, or amend this promotion without notice.

Product name change
As part of the continuous evolution of our portfolio, we have changed the name of our range to Mimix™ reference standards to better reflect the patient-like performance they provide.

While our product range has a new name, everything you rely on remains the same:

Identical formulation and performance
Same part numbers and SKUs
Existing protocols and procedures
Same technical specifications
Quality and reliability you trust

No action is required from you. Future orders, product labels, documentation, and communications will reference the new product name.

Colorectal cancers (CRC) are the second most leading cause of cancer deaths worldwide (2020). To aid in the early diagnosis and direct treatment trajectories for CRC patients, molecular/genetic profiling is invaluable. Our new CRC circulating tumor DNA (ctDNA) reference panel is made with a unique blend of engineered cell lines with clinically relevant mutations specific to CRCs. This panel mimics ctDNA and can be used as a reference material to validate NGS and other molecular biology workflows for the detection of key actionable mutations in genes like AKT1, APC, BRAF, KRAS, PIK3CA and TP53 (please refer table below to see full list of genes). The allelic frequencies for the variants in the panel are as low as 1.25% with a scope of diluting further using our matched Negative Control - HD843, enabling assessment of minimal residual disease (MRD) typically replicating post-surgery and post-adjuvant treatment conditions. This reference material can also be used to validate companion diagnostic (CDx) tests which are used for tailoring treatments depending on the genetic make-up of the tumors for improved prognosis. The CRC ctDNA reference panel is a blend of highly characterized, cell line derived, clinically relevant mutations manufactured under ISO 9001:2015 and ISO 13485:2016.

Technical data

Format: ctDNA

Genes covered: ABL1, ALK, AKT1, APC, BRAF, PIK3CA, KRAS, NRAS, PTEN, TP53

Allelic frequencies: 1.25% - 8.00%

Buffer: Tris-EDTA (10mM Tris-HCl, 1mM EDTA), pH 8.0

Product information

Fragment size: 160 bp

Unit size: 350 ng per vial

Concentration: 20 ng/µl

Verified mutations:

Gene	DNA sequence change	Amino acid change	Expected allelic frequency (%)
ABL1	c.1001C>T	p.T315I	1.25
ALK	c.3522C>A	p.F1174L	2.50
AKT1	c.49G>A	p.E17K	1.25
APC	c.8140C>T	p.R2714C	8.00
BRAF	c.1799T>A	p.V600E	1.25
PIK3CA	c.1624G>A	p.E542K	1.88
KRAS	c.35G>A	p.G12D	2.50
NRAS	c.181C>A	p.Q61K	1.25
PTEN	c.388C>T	p.R130*	2.50
TP53	c.722C>T	p.S241F	2.50

General information

Storage: 4°C

Expiration: See all product shelf life information

Quality control

Fragmentation size: D1000 DNA ScreenTape assay

Allelic frequency: Droplet Digital™ PCR

Quantification: Qubit® dsDNA BR assay (Invitrogen)

Intended use: For assay developers and molecular diagnostic labs for routine performance monitoring of molecular biology assays. Research use only. Not for diagnostic procedures.